Biocon Biologics' Yesafili to enter US market, after agreement with Regeneron
Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of 2026. Approved by the USFDA as an interchangeable biosimilar to Eylea, Yesafili targets vision-related conditions. A similar settlement in Canada paves the way for a launch there by July 1, 2025.
Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of 2026. Approved by the USFDA as an interchangeable biosimilar to Eylea, Yesafili targets vision-related conditions. A similar settlement in Canada paves the way for a launch there by July 1, 2025.
